US FDA Approves AbbVie's Rare Blood Cancer Drug
US FDA Approves AbbVie's Rare Blood Cancer Drug
The U.S. Food and Drug Administration on Wednesday approved AbbVie's drug to treat blastic plasmacytoid dendritic cell neoplasm, a very rare type of blood cancer. This approval provides a new treatment option for patients with limited choices.
Drug Details and Risks
The drug, pivekimab sunirine‑pvzy, is administered intravenously once every three weeks. The FDA has issued a boxed warning for serious liver problems, including a condition where blood flow in the liver is blocked. Other risks include infusion reactions and fluid buildup.
AbbVie's shares rose over 1% in afternoon trading. The approval is particularly significant for patients whose disease has returned or did not respond to prior treatment.
Impacted Symbols
Symbols affected by this headline and their sentiment signals
The news, analyses, and comments on this platform do not constitute investment advice. When making investment decisions, you should conduct your own research and consult with a qualified financial advisor if necessary. FiNews cannot be held responsible for any losses that may arise from the use of this information.